Related Experiment Video
Updated: May 16, 2025
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
Precision Drug Delivery to the Liver: A Nanoparticle Approach
Krishna Yadav1, Ajazuddin1, Mukesh Sharma1
1Rungta College of Pharmaceutical Sciences and Research, Kohka, Bhilai 490024, India.
Abstract:
The global burden of Chronic Liver Diseases (CLDs) is escalating, with increasing prevalence and mortality. Various conditions ranging from fibrosis, cirrhosis, and hepatocellular carcinoma are associated with conditions such as toxin accumulation, viral infections, and metabolic derangements. In this already difficult context, the emergence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis complicated the picture even further. While there has been much advancement in medical research, there is currently no standard cure; hence, the best treatment options are limited, providing a rising need for new therapeutic approaches. Nanoparticle drug delivery systems represent a promising avenue, providing targeted delivery and enhanced therapeutic effectiveness. Nanosystems can protect therapeutic agents from degradation, evade rapid clearance mechanisms, and target drugs directly to a specific hepatic cell type. However, the complex architecture of the liver presents challenges for these therapies, including the need to precisely target individual cells and retain the stability of nanoparticles within the hepatic microenvironment. This review presents recent advances in nanoparticle and targeted ligands-based technologies. These technologies help to navigate barriers associated with similar therapies. As these challenges are addressed, nanotechnological advancements could potentially lead to a major revolution in the treatment of CLDs, paving the way for improved management strategies and providing new hope for affected individuals worldwide.
Insights
Nanoparticle drug delivery offers new hope for chronic liver diseases (CLDs). These systems enhance drug effectiveness by targeting specific liver cells, addressing limitations in current CLD treatments.
Area of Science:
- Hepatology and Nanomedicine
- Drug Delivery Systems
- Biotechnology
Background:
- Chronic Liver Diseases (CLDs) present a growing global health challenge with increasing prevalence and mortality.
- Existing conditions like fibrosis, cirrhosis, and hepatocellular carcinoma are compounded by emerging diseases such as metabolic dysfunction-associated steatotic liver disease.
- Current therapeutic options for CLDs are limited, highlighting an urgent need for novel treatment strategies.
Purpose of the Study:
- To review recent advancements in nanoparticle and targeted ligand-based technologies for treating Chronic Liver Diseases.
- To explore how nanotechnologies can overcome challenges in hepatic drug delivery.
- To assess the potential of nanomedicine in revolutionizing CLD management.
Main Methods:
- Review of current literature on nanoparticle drug delivery systems for liver diseases.
- Analysis of targeted ligand strategies for specific hepatic cell targeting.
- Evaluation of nanocarrier stability and efficacy within the hepatic microenvironment.
Main Results:
- Nanoparticle systems show promise in protecting therapeutic agents from degradation and rapid clearance.
- Targeted delivery via nanosystems can enhance drug effectiveness by directing agents to specific hepatic cell types.
- Advancements in nanoparticle and ligand technologies are helping to navigate delivery barriers in the complex liver architecture.
Conclusions:
- Nanoparticle-based therapies represent a promising frontier for treating Chronic Liver Diseases.
- Overcoming challenges in precise cellular targeting and nanoparticle stability is key to realizing nanomedicine's potential in hepatology.
- Further development in nanotechnological approaches could lead to significant improvements in CLD management and patient outcomes.
